CN101558081B - 用于诊断和治疗应用的纤维蛋白结合肽缀合体 - Google Patents

用于诊断和治疗应用的纤维蛋白结合肽缀合体 Download PDF

Info

Publication number
CN101558081B
CN101558081B CN200780045892.5A CN200780045892A CN101558081B CN 101558081 B CN101558081 B CN 101558081B CN 200780045892 A CN200780045892 A CN 200780045892A CN 101558081 B CN101558081 B CN 101558081B
Authority
CN
China
Prior art keywords
compound
formula
fibrin
chelating
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200780045892.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN101558081A (zh
Inventor
E·马里奈利
K·拉迈林加姆
R·斯文森
宋波
L·拉图塔
F·尤吉里
V·洛鲁索
S·艾米
P·莫洛希尼
L·查阿巴尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bracco Imaging SpA
Original Assignee
Bracco Imaging SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bracco Imaging SpA filed Critical Bracco Imaging SpA
Publication of CN101558081A publication Critical patent/CN101558081A/zh
Application granted granted Critical
Publication of CN101558081B publication Critical patent/CN101558081B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/124—Macromolecular compounds dendrimers, dendrons, hyperbranched compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
CN200780045892.5A 2006-12-11 2007-12-11 用于诊断和治疗应用的纤维蛋白结合肽缀合体 Expired - Fee Related CN101558081B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86947206P 2006-12-11 2006-12-11
US60/869,472 2006-12-11
PCT/EP2007/063659 WO2008071679A1 (en) 2006-12-11 2007-12-11 Fibrin binding peptide conjugates for diagnostic and therapeutic applications.

Publications (2)

Publication Number Publication Date
CN101558081A CN101558081A (zh) 2009-10-14
CN101558081B true CN101558081B (zh) 2014-08-20

Family

ID=39232769

Family Applications (2)

Application Number Title Priority Date Filing Date
CN200780045892.5A Expired - Fee Related CN101558081B (zh) 2006-12-11 2007-12-11 用于诊断和治疗应用的纤维蛋白结合肽缀合体
CN2007800458747A Expired - Fee Related CN101573143B (zh) 2006-12-11 2007-12-11 纤维蛋白结合肽及其缀合体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2007800458747A Expired - Fee Related CN101573143B (zh) 2006-12-11 2007-12-11 纤维蛋白结合肽及其缀合体

Country Status (5)

Country Link
US (3) US9333272B2 (cg-RX-API-DMAC7.html)
EP (2) EP2111237B1 (cg-RX-API-DMAC7.html)
JP (2) JP5364589B2 (cg-RX-API-DMAC7.html)
CN (2) CN101558081B (cg-RX-API-DMAC7.html)
WO (2) WO2008073458A2 (cg-RX-API-DMAC7.html)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7208727B2 (en) * 2003-01-14 2007-04-24 Georgia Tech Research Corporation Electrospray systems and methods
WO2008073458A2 (en) * 2006-12-11 2008-06-19 Bracco Imaging S.P.A. Fibrin-binding peptides and conjugates thereof
EP2274009B1 (en) * 2008-03-28 2013-11-13 GlaxoSmithKline LLC Methods of treatment
EP2346532B1 (en) 2008-10-07 2020-10-07 Bracco Suisse SA Targeting construct comprising anti-polymer antibody and microvesicles binding to the same
EP2384323A4 (en) 2008-11-11 2013-07-31 Univ Nanyang Tech INTRAVASCULAR CONTRASTING AGENTS
US8293213B2 (en) * 2009-03-12 2012-10-23 Palo Alto Research Center Incorporated Method and apparatus for thrombus removal using magnetic particles
AU2010226479A1 (en) 2009-03-19 2011-09-22 Wyeth Llc Methods for the preparation of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7) -en-2-yl)ethyl]phosphonic acid and precursors thereof
WO2010121133A2 (en) 2009-04-17 2010-10-21 The General Hospital Corporation Multimodal imaging of fibrin
GB0910013D0 (en) * 2009-06-10 2009-07-22 Ge Healthcare Ltd PET imaging of fibogenesis
CA2777841C (en) 2009-11-02 2017-01-17 Francis M. Creighton Magnetomotive stator system and methods for wireless control of magnetic rotors
JP2012000072A (ja) * 2010-06-18 2012-01-05 Japan Health Science Foundation 新規な抗フィブリン抗体
AU2012214419B2 (en) * 2011-02-09 2015-12-24 Glaxosmithkline Llc Lyophilized formulations
TW201245221A (en) * 2011-05-02 2012-11-16 Baxter Int FGF based fibrin binding peptides
EP2771478B1 (en) 2011-10-25 2018-03-14 The Scripps Research Institute Synthesis of libraries of peptide tertiary amides
US20130195752A1 (en) 2012-02-01 2013-08-01 Regents Of The University Of Minnesota Functionalized nanoparticles and methods of use thereof
EP2822605A1 (en) 2012-03-05 2015-01-14 Bracco Imaging S.p.A Dynamic contrast enhanced mri method and agents for the assessment of the macromolecular transport within pathologic tissues
US9883878B2 (en) 2012-05-15 2018-02-06 Pulse Therapeutics, Inc. Magnetic-based systems and methods for manipulation of magnetic particles
KR101474063B1 (ko) 2012-05-23 2014-12-19 동국대학교 산학협력단 피브린 표적 펩타이드 서열이 결합된 글라이콜 키토산-금 나노입자를 포함하는 혈전 탐지용 ｃｔ 조영제
US9849201B2 (en) 2013-05-03 2017-12-26 Washington University Homing agents
US10231993B2 (en) * 2013-06-27 2019-03-19 University Of Washington Through Its Center For Commercialization Biocompatible polymeric system for targeted treatment of thrombotic and hemostatic disorders
KR20150010908A (ko) * 2013-07-21 2015-01-29 더 스테이트 유니버시티 오브 뉴욕 버팔로 결합된 광음향 및 초음파 이미징용 조영제
US10471163B2 (en) 2013-09-13 2019-11-12 The General Hospital Corporation Activatable fibrin-binding probes
CN103664701A (zh) * 2013-11-29 2014-03-26 成都普康生物科技有限公司 [2-[2-(Fmoc-氨基)乙氧基]乙氧基]乙酸合成路线
JP6461973B2 (ja) 2013-12-20 2019-01-30 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ２以上の疎水性ドメインおよびｐｅｇ部分を含む親水性ドメインを含む化合物の、細胞の安定化のための使用
WO2015091958A1 (en) 2013-12-20 2015-06-25 Roche Diagnostics Gmbh Compounds comprising one or more hydrophobic domains and a hydrophilic domain comprising peg moieties, useful for binding cells
JP6302560B2 (ja) 2013-12-20 2018-03-28 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ポリエチレングリコール部分を含む化合物を用いて支持体に細胞を固定化する方法
EP3223866B1 (en) 2014-11-25 2023-03-08 Bristol-Myers Squibb Company Methods and compositions for 18f-radiolabeling of the fibronectin type (iii) domain
EP3702367B1 (en) 2014-11-25 2024-05-15 Bristol-Myers Squibb Company Novel pd-l1 binding polypeptides for imaging
JP6804095B2 (ja) * 2015-06-10 2020-12-23 学校法人帝京大学 セラノスティクス用のバブル製剤（ｔｂ）及びその使用方法
CN108136053B (zh) 2015-08-13 2022-05-27 通用医疗公司 用于mr分子成像的基于锰的螯合缀合物
US11370826B2 (en) 2016-02-09 2022-06-28 Bracco Suisse Sa Recombinant chimeric protein for selectins targeting
CN109562195A (zh) 2016-06-01 2019-04-02 百时美施贵宝公司 用pd-l1结合多肽进行pet成像
WO2017210335A1 (en) 2016-06-01 2017-12-07 Bristol-Myers Squibb Company Imaging methods using 18f-radiolabeled biologics
US11918315B2 (en) 2018-05-03 2024-03-05 Pulse Therapeutics, Inc. Determination of structure and traversal of occlusions using magnetic particles
CN109316608B (zh) * 2018-10-31 2021-09-28 重庆医科大学附属第二医院 一种低强度聚焦超声响应型相变溶栓纳米粒、应用及其制备方法
JP7744240B2 (ja) * 2018-11-12 2025-09-25 ブラッコ・イメージング・ソシエタ・ペル・アチオニ キレート化ａａｚｔａコンジュゲートおよびその錯体
SG11202104497VA (en) * 2018-12-18 2021-05-28 Bracco Suisse Sa Optimized process for dimeric peptide-phospholipid conjugate
CN120919356A (zh) * 2019-06-05 2025-11-11 微脉管治疗有限公司 检测和治疗血栓形成和血管斑块的组合物和方法
CN110237256A (zh) * 2019-07-22 2019-09-17 重庆医科大学 一种载n2o微泡及其制备方法与应用
KR102333606B1 (ko) * 2019-10-15 2021-12-01 주식회사 엔지켐생명과학 1-팔미토일-2-리놀레오일-3-아세틸 글리세롤의 제조 방법
EP4048324A4 (en) * 2019-10-23 2024-05-15 Collagen Medical, LLC Fibrin-binding compounds for imaging and treatment
CN111041025B (zh) * 2019-12-17 2021-06-18 深圳市瑞吉生物科技有限公司 基于结合N-乙酰半乳糖胺多肽的mRNA靶向分子及其制备方法
CN111744019B (zh) 2020-07-01 2023-08-04 深圳瑞吉生物科技有限公司 基于甘露糖的mRNA靶向递送系统及其应用
US12171443B1 (en) 2021-03-09 2024-12-24 Pulse Therapeutics, Inc. Magnetically controlled flow generation
WO2023032994A1 (ja) 2021-08-31 2023-03-09 富士フイルム株式会社 化合物及びこれを用いた標識生体物質
CN118725025A (zh) * 2024-06-04 2024-10-01 厦门稀土材料研究所 用于177Lu标记的三齿类酰胺酸型双功能螯合剂及其制备方法和应用
CN120668837B (zh) * 2025-08-18 2025-10-31 复星安特金(成都)生物制药有限公司 一种检测消泡剂204的方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362476A (en) 1984-10-18 1994-11-08 Board Of Regents, The University Of Texas System Alkyl phosphonate polyazamacrocyclic cheates for MRI
MX174467B (es) 1986-01-23 1994-05-17 Squibb & Sons Inc 1,4,7-triscarboximetil-1,4,7,10-tetraazaciclodo decano substituido en 1 y compuestos analogos
US5021556A (en) 1987-07-22 1991-06-04 Neorx Corporation Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides
DK483587D0 (da) * 1987-09-15 1987-09-15 Riemann & Co Aps Claus Antiperspirant praeparat
US5075099A (en) 1988-05-31 1991-12-24 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
US5118797A (en) 1989-08-28 1992-06-02 E. R. Squibb & Sons, Inc. Rhenium tris dioxime complexes
CA2034042C (en) 1990-01-18 1999-08-17 Adrian D. Nunn Boronic acid adducts of rhenium dioxime and technetium-99m dioxime complexes containing a biochemically active group
US5183653A (en) 1990-04-13 1993-02-02 E. R. Squibb & Sons, Inc. Boronic acid adducts of metal dioxime complexes useful in labelling proteins and other amine-containing compounds
US5367080A (en) 1990-11-08 1994-11-22 Sterling Winthrop Inc. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods
US5965107A (en) 1992-03-13 1999-10-12 Diatide, Inc. Technetium-99m labeled peptides for imaging
US5808091A (en) 1991-10-29 1998-09-15 Bracco International B.V. Rhenium and technetium complexes containing a hypoxia localizing moiety
US5608110A (en) 1993-06-15 1997-03-04 Bracco International B.V. Heteroatom-bearing ligands and metal complexes thereof
ES2114209T3 (es) 1993-07-19 1998-05-16 Resolution Pharm Inc Queladores de radionuclidos de tipo hidrazino que tienen una configuracion n3s.
US5409689A (en) 1993-08-13 1995-04-25 Concat, Ltd. MRI image enhancement using complexes of paramagnetic cations and amine ligands containing a mixture of phosphonate and non-phosphonate pendant arms
US5574140A (en) 1993-09-03 1996-11-12 Resolution Pharmaceutical Inc. Hydrazino-type N2 S2 chelators
US5662885A (en) 1994-07-22 1997-09-02 Resolution Pharmaceuticals Inc. Peptide derived radionuclide chelators
DE4445065A1 (de) 1994-12-07 1996-06-13 Diagnostikforschung Inst Verfahren zur In-vivo-Diagnostik mittels NIR-Strahlung
GB9502065D0 (en) 1995-02-02 1995-03-22 Nycomed Imaging As Contrast media
DE69628731T3 (de) * 1995-11-01 2012-09-20 Bracco Suisse S.A. Gezielte magnetisch markierte molekularmarkersysteme als nmr-bilderzeugungsmittel
EP0946202B1 (en) 1996-10-28 2003-09-10 Amersham Health AS Contrast agents
DE19717904A1 (de) 1997-04-23 1998-10-29 Diagnostikforschung Inst Säurelabile und enzymatisch spaltbare Farbstoffkonstrukte zur Diagnostik mit Nahinfrarotlicht und zur Therapie
US5886142A (en) 1997-05-20 1999-03-23 Thomas Jefferson University Radiolabeled thrombus imaging agents
US6093382A (en) 1998-05-16 2000-07-25 Bracco Research Usa Inc. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
JP2003508027A (ja) * 1999-07-29 2003-03-04 ダイアックス コーポレイション フィブリン結合性部分
IT1315263B1 (it) 1999-12-21 2003-02-03 Bracco Spa Composti chelanti,loro chelati con ioni metallici paramagnetici, loropreparazione ed uso
EP1348026A2 (en) * 2000-12-23 2003-10-01 Dyax Corp. Fibrin binding moieties useful as imaging agents
US6984373B2 (en) * 2000-12-23 2006-01-10 Dyax Corp. Fibrin binding moieties useful as imaging agents
US7893223B2 (en) * 2001-07-17 2011-02-22 Bracco Imaging S.P.A. Multidentate AZA ligands able to complex metal ions and the use thereof in diagnostics and therapy
ITMI20011518A1 (it) 2001-07-17 2003-01-17 Bracco Imaging Spa Leganti azotati multidentati capaci di complessare ioni metallici e loro uso in diagnostica e in terapia
CA2461836A1 (en) * 2001-10-16 2003-04-24 Epix Medical, Inc. Detection and treatment of intravascular lesions
WO2008073458A2 (en) * 2006-12-11 2008-06-19 Bracco Imaging S.P.A. Fibrin-binding peptides and conjugates thereof

Also Published As

Publication number Publication date
EP2111237B1 (en) 2015-03-18
JP2010512369A (ja) 2010-04-22
EP2097438B1 (en) 2015-08-26
EP2097438A1 (en) 2009-09-09
JP5345945B2 (ja) 2013-11-20
US8466107B2 (en) 2013-06-18
EP2111237A2 (en) 2009-10-28
CN101573143A (zh) 2009-11-04
WO2008071679A1 (en) 2008-06-19
WO2008073458A3 (en) 2008-10-02
CN101558081A (zh) 2009-10-14
US8278274B2 (en) 2012-10-02
WO2008071679A9 (en) 2009-01-15
CN101573143B (zh) 2013-04-24
WO2008073458A2 (en) 2008-06-19
US20100158814A1 (en) 2010-06-24
US9333272B2 (en) 2016-05-10
EP2111237A4 (en) 2011-04-13
US20120328512A1 (en) 2012-12-27
US20100202967A1 (en) 2010-08-12
JP5364589B2 (ja) 2013-12-11
JP2010512400A (ja) 2010-04-22

Similar Documents

Publication Publication Date Title
CN101558081B (zh) 用于诊断和治疗应用的纤维蛋白结合肽缀合体
US10653801B2 (en) Targeting peptides and methods of use
AU768859B2 (en) Binding moieties for fibrin
JP4948742B2 (ja) ペプチド系化合物
US11738099B2 (en) Molecular probes and methods of use
JP2010512400A5 (cg-RX-API-DMAC7.html)
KR20080036662A (ko) 펩티드 기재 화합물
US9284381B2 (en) Methods and reagents for preparing multifunctional probes
US9200017B2 (en) Multimodal imaging of fibrin
JP2025063147A (ja) 腫瘍細胞外マトリックスにおける腫瘍性タンパク質に特異的なペプチドｐｅｔ／ｓｐｅｃｔプローブ
CN1309661A (zh) 标记的谷氨酰胺和赖氨酸类似物
KR20070029200A (ko) 펩티드계 화합물
US9889213B2 (en) Multimodal imaging of fibrin

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140820

CF01 Termination of patent right due to non-payment of annual fee